Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4716320 | 0.98 | MAOB (0.56) | MAOBMAOAGAAMAPTRAB9A | |
| SCHEMBL13577224 | 0.86 | MAOB (0.58) | MAOBMAOAGAAMAPTRAB9A | |
| SCHEMBL29502845 | 0.86 | MAOB (0.58) | MAOBMAOAGAAMAPTRAB9A | |
| SCHEMBL3505720 | 0.86 | MAOB (0.64) | MAOBMAOA | |
| SCHEMBL13862125 | 0.86 | MAOB (0.43) | MAOBMAOAGAAMAPTRAB9A | |
| SCHEMBL3364162 | 0.85 | MAOB (0.69) | MAOBMAOA | |
| SCHEMBL4473165 | 0.84 | MAOB (0.63) | MAOBMAOAGAAMAPTRAB9A | |
| SCHEMBL30040891 | 0.84 | MAOB (0.63) | MAOBMAOAGAAMAPTRAB9A | |
| SCHEMBL15817 | 0.84 | ALOX5 (0.61) | MAOBMAOAGAAMAPTRAB9A | |
| SCHEMBL29263961 | 0.83 | NPC1 (0.60) | MAOBMAOARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115322199-B | Compounds and their use in the treatment of schistosomiasis | 默克专利股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| CN-118684667-A | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-112512636-B | Compounds for the treatment of fasciolopsis | 默克专利股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-117466897-A | Highly selective FGFR2 inhibitors | 深圳福沃药业有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-115322199-A | Compounds and their use in the treatment of schistosomiasis | 默克专利股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-110461848-B | Compounds and their use in the treatment of schistosomiasis | 默克专利股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-20210230169-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS | MERCK PATENT GMBH (DE) | 2021-07-29 | — | — | US | disclosed |
| US-11046700-B2 | Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis | MERCK PATENT GMBH (DE) | 2021-06-29 | — | — | US | disclosed |
| WO-2003076443-A9 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2005-01-20 | — | — | WO | disclosed |
| EP-1483266-A1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-6803372-B2 | SUCH AS CIS-N-(4-BENZOYLPHENYL)-4-HYDROXY-3'-OXOSPIRO (CYCLOHEXANE-1,1' (3'H)-ISOBENZOFURAN)-4-CARBOXAMIDE FOR USE AS NEUROPEPTIDE Y RECEPTOR ANTAGONIST FOR TREATMENT BULIMIA, OBESITY OR DIABETES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-10-12 | — | — | US | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| CN-1478078-A | Nitrogen-containing aromatic ring derivatives | ������������ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| WO-2003076443-A1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | WO | disclosed |
| CN-1395565-A | Indole derivatives as MCP-1 receptor antagonists | ASTRAZENECA AB (SE) | 2003-02-05 | — | — | CN | disclosed |
| US-20020188124-A1 | Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes | MSD K.K. (JP) | 2002-12-12 | — | — | US | disclosed |
| US-5622967-A | NERVOUS SYSTEM DISORDERS | STERLING WINTHROP, INC. (US) | 1997-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188124-A1 | Such as cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro (cyclohexane-1,1' (3'H)-isobenzofuran)-4-carboxamide for use as neuropeptide Y receptor antagonist for treatment bulimia, obesity or diabetes | NPY1R, GPR119, NPY2R | MAOB 586/4885MAOA 767/4885GAA 1206/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | MAOB 695/4885MAOA 627/4885GAA 1408/4885 |
| US-20210230169-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FASCIOLIASIS | SLC10A1, SLC10A2, MGST3 | MAOB 276/4885MAOA 102/4885GAA 178/4885 |
| US-11046700-B2 | Substituted imidazo[1,2-a]pyrazines, pyrazolo[1,5-c]pyrimidines, pyrazolo[1,5-a]pyridines, and purines for the treatment of schistosomiasis | P2RY1, P2RX5, TPMT | MAOB 1829/4885MAOA 786/4885GAA 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.